ClinicalTrials.gov
ClinicalTrials.gov Menu

Specimen Banking From Patients With Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01585675
Recruitment Status : Recruiting
First Posted : April 26, 2012
Last Update Posted : June 15, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The primary objective of the protocol is to develop a comprehensive specimen banking program from patients with lung cancer for future translation research, which will enable the investigators to detect lung cancer earlier, develop better therapies and explore screening and prevention strategies.

Condition or disease
Lung Neoplasms

Detailed Description:
The aims of the study are as follows: 1) to continue to unravel the complex biology of lung cancer 2) to identify early detection and prognostic markers to guide therapeutic decision 3) to define markers of response and/or resistance to drug therapy, and 4) to identify new therapeutic and prevention targets.

Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Specimen Banking From Patients With Lung Cancer
Study Start Date : November 2005
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Group/Cohort
Diagnosis/treatment of lung cancer
Specimen Banking



Primary Outcome Measures :
  1. Development of a comprehensive specimen banking program from patients with lung cancer for future translational research. [ Time Frame: 6 years ]
    No statistical analysis will be applied to the overall collection of samples. Rather, each project that utilized tissue bank resources will require an appropriate statistical plan to be submitted along with the initial tissue request.


Biospecimen Retention:   Samples With DNA
Tissue, blood, urine, and sputum, breath


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.
Criteria

Inclusion Criteria:

  1. Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.
  2. Oral and written informed consent

Exclusion Criteria:

1. Any individual who does not give oral and written consent for participation


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01585675


Contacts
Contact: Mary K. Jackson 303-724-1650 mary.k.jackson@ucdenver.edu

Locations
United States, Colorado
University of Colorado Cancer Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Mary K. Jackson    303-724-1650    mary.k.jackson@ucdenver.edu   
Principal Investigator: Adriaan VanBokhoven, PhD         
Sponsors and Collaborators
University of Colorado, Denver
National Cancer Institute (NCI)
Investigators
Principal Investigator: Adriaan VanBokhoven, PhD University of Colorado, Denver

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT01585675     History of Changes
Other Study ID Numbers: 04-0688
P50CA058187 ( U.S. NIH Grant/Contract )
First Posted: April 26, 2012    Key Record Dates
Last Update Posted: June 15, 2018
Last Verified: June 2018

Keywords provided by University of Colorado, Denver:
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases